Tvardi Therapeutics Q2 net income $4.2M; IPF Phase 2 topline data on track for Q4 2025

Tvardi Therapeutics, Inc.

2025-Q2 EPS reported -$2.04

Net income of $4.2M vs. net loss of $7.0M in Q2 2024; driven by $12.8M remeasurement gain on convertible notes.
Basic EPS of $0.51; diluted EPS loss of $1.00.
R&D expenses $5.8M (down $0.7M YoY); G&A expenses $3.1M (up $2.4M due to merger costs).
Cash, equivalents, and short-term investments $41.0M as of June 30, 2025; runway into Q4 2026.
REVERT IPF Phase 2 trial fully enrolled; topline data expected Q4 2025. IND for TTI-109 submitted to FDA in June 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.